y•½¬24”N“xz
183) ›“y‹‰ë”üAŠì“TŽqA‘êˆêA•è—E“ñA‡—t “N–çF
‹}«‹ÇЉŠÇ‚É”º‚¤–ò•¨ŠÌ‘ãŽÓŠˆ«‚̕ϓ®ƒƒJƒjƒYƒ€‚ÌŒŸ“¢.
“ú–{–òŠw‰ï‘æ133”N‰ïC‰¡•lŽsC3.27-30, 2013.
182) ›Atsushi Osanaga, Keiichi Makinodan, Tatsuya Sakiyama, Tetsuya Aiba and Yuji Kurosaki:
Evaluation of dynamic diffusion process for developing focally acting DDSs: Improvement of focal bioavailability by topical cooling.
‘æ6‰ñŽŸ¢‘ã‚ð’S‚¤ŽáŽèˆã—Öò‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€C‹ž“sŽsC11.23-24, 2012.
181) ›Yukiko Takahata, Risa Takaki, Mizuki Horiuchi, Soichiro Moriyama, Tetsuya Aiba and Yuji Kurosaki:
Effect of intraperitoneal lipid emulsions on plasma-to-peritoneal transfer of lipophilic drugs in rats.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ27‰ñ”N‰ïC“Œ‹žC11.20-22, 2012.
180) ›Noriko Kajikawa, Masami Doi, Jun-ichi Kusaba, Yuji Kurosaki and Tetsuya Aiba:
Effects of acute local inflammation on the hepatic expressions of the CYP3A subfamily in rats.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ27‰ñ”N‰ïC“Œ‹žC11.20-22, 2012.
179) ›‚–Ø—ŽÑA‚”¨—F‹IŽqA–x“àŽ÷AXŽR‘ˆê˜YA‡—t “N–çA•è —E“ñF
• o“à‚É’“ü‚µ‚½Ž‰–b“ûÜ‚ªŒŒŸ÷’†‹y‚Ñ• o“à–ò•¨“®‘Ô‚É‹y‚Ú‚·‰e‹¿Fމ—n«‚̈قȂé–ò•¨‚ł̔äŠrŒŸ“¢.
‘æ51‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC¼]ŽsC11.10-11, 2012.
178) ›“y‹‰ë”üAŠì“TŽqA‘êˆêA•è—E“ñA‡—t “N–çF
ƒ‰ƒbƒgŠÌCYP3A‘ãŽÓŠˆ«‚É‹y‚Ú‚·‹}«‹ÇЉŠÇ‚̉e‹¿.
‘æ51‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC¼]ŽsC11.10-11, 2012.
177) ›–q”V’i ŒhˆêA“Œ‰¶”[ ŽiAèŽR ’B–îA‡—t “N–çA•è —E“ñF
Microdialysis–@‚ð—p‚¢‚½–ò•¨‚̋ؓ÷“à‹ÇŠ“®‘Ô•]‰¿:‹ÇŠ—â‹p‚É‚æ‚é‹ÇŠ–ò•¨—˜—p—¦‚Ì‘‘å.
‘æ28‰ñ“ú–{DDSŠw‰ïŠwpW‰ïCŽD–yŽsC7. 4-5, 2012.
176) ›¬ì@“ÖA X@‘×—TA ‚‹´@•‘A ‡—t“N–çA •è—E“ñF
޼—Ö@—p”í•¢Œ^ŠO—pŠî܂Ƃµ‚Ä‚ÌL-HPCŠÜ…ƒQƒ‹ƒV[ƒg‚̻ܓI“Á«•]‰¿.
“ú–{–òÜŠw‰ï‘æ27”N‰ïC_ŒËŽsC5.24-26, 2012.
175) ›Œã“¡—SŽqA ‘C“c‚ ‚ä‚ÝA •ú±—E“ñA ‡—t“N–çF
ƒ‰ƒbƒg‚É‚¨‚¯‚éƒLƒgƒTƒ“‚ð—p‚¢‚½“ï‹zŽû«RƒEƒBƒ‹ƒX–ò‚ÌÁ‰»ŠÇ‹zŽû‰ü‘P.
“ú–{–òÜŠw‰ï‘æ27”N‰ïC_ŒËŽsC5.24-26, 2012.
174) ›èŽR’B•vA‰ª ‘åŽkAƒg[ƒ}ƒXEƒWƒFƒŠƒ}ƒ„A‡—t“N–çA•ú±—E“ñF
މ–b“ûÜ”÷¬“§Í–@iLipo-MD–@j‚É‚æ‚ée–û«–ò•¨‚̋NJ“®‘Ôƒ‚ƒjƒ^“Á«‚̉ü‘P.
“ú–{–òÜŠw‰ï‘æ27”N‰ïC_ŒËŽsC5.24-26, 2012.
y•½¬23”N“xz
173) ›‰ª“c~–FC‰Í–쌒‘¾˜YCÎ쉷ŽqCâ]—˜ŒbC‡—t“N–çCìú±”ŽŒÈC•è—E“ñF
ƒ‰ƒbƒg”]Ò‘‰t‚Ì“d‰ðŽ¿•½t’²ß‹@\‚É‹y‚Ú‚·‹}«‰ŠÇ‚̉e‹¿.
“ú–{–òŠw‰ï‘æ132”N‰ïCŽD–yŽsC3.28-31, 2012.
172) ›‡—t“N–çC‘ºã—RŽ÷C´…N³Cì“c_•½C’†ŽR^—ŽqC¬Š}Œ´–¾”üC‰ª“c~–FC•è—E“ñC‰Á—ˆ“c”Ž‹MF
V‹KRXRƒAƒSƒjƒXƒg‹y‚Ñ‚»‚Ì—Þ‰‰»‡•¨‚̃qƒgŠÌ‚É‚¨‚¯‚é‘ãŽÓ“Á«‚Ì—\‘ª.
“ú–{–òŠw‰ï‘æ132”N‰ïCŽD–yŽsC3.28-31, 2012.
171) ›•è—E“ñF
ƒgƒ‰ƒCƒAƒ‹•]‰¿‚ÌŠT—vF‘—§‘åŠw‚Ì—§ê‚©‚ç.iˆê”ʃVƒ“ƒ|ƒWƒEƒ€u‚U”N§–òŠw‹³ˆçƒvƒƒOƒ‰ƒ€‚Ì‘æŽOŽÒ•]‰¿`ƒgƒ‰ƒCƒAƒ‹‚©‚ç–{•]‰¿‚Ö`vCƒgƒ‰ƒCƒAƒ‹•]‰¿‚ÌŠT—vj
“ú–{–òŠw‰ï‘æ132”N‰ïCŽD–yŽsC3.28-31, 2012.
170) ›Kentaro Kono, Atsuyoshi Okada, Atsuko Ishikawa, Rie Sakae, Hiromu Kawasaki, Yuji Kurosaki and Tetsuya Aiba:
Effect of acute inflammation on lithium disposition to cerebrospinal fluid in rats
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ26‰ñ”N‰ïCL“‡ŽsC11.16-18, 2011.
169) ›Yoshiki Murakami, Yasumasa Shimizu, Kohei Kawata, Mariko Nakayama, Akemi Ogasawara, Yuji Kurosaki, Tetsuya Aiba and Hirotaka Kakuta:
Metabolic properties of novel retinoid X receptor agonists possessing various side chain structures in liver microsomes
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ26‰ñ”N‰ïCL“‡ŽsC11.16-18, 2011.
168) ›Mahira Hashim, Hiroyuki Miyachi, Thomas Jeremiah, Tetsuya Aiba and Yuji Kurosaki:
Studies on the biopharmaceutical characteristics of novel PPAR pan-agonist, TIPP-703, and its pharmaceutical modification to improve intestinal absorption.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ26‰ñ”N‰ïCL“‡ŽsC11.16-18, 2011.
167) ›‰ª“c~–FA‰Í–쌒‘¾˜YAÎ쉷ŽqAâ]—˜ŒbAìú±”ŽŒÈA•ú±—E“ñA‡—t“N–çF
‹}«‰ŠÇ‚É”º‚¤“d‰ðŽ¿‚Ì”]Ò‘‰tˆÚs“Á«‚̕ϓ®•]‰¿.
‘æ50‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC‚¼ŽsC11.12-13, 2011.
166) ›´…N³A‘ºã—RŽ÷Aì“c_•½A’†ŽR^—ŽqA¬Š}Œ´–¾”üA•ú±—E“ñA‡—t“N–çA‰Á—ˆ“c”Ž‹MF
V‹KœŠi‚ð—L‚·‚éRXRƒAƒSƒjƒXƒg‚Ì‘¤½\‘¢‚ÆŠÌ‘ãŽÓŠˆ«‚Ì‘ŠŠÖ‰ðÍ.
‘æ50‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC‚¼ŽsC11.12-13, 2011.
165) ›‚”¨—F‹IŽqA–x“àŽ÷AXŽR‘ˆê˜YA‡—t“N–çA•è—E“ñF
• o“à\‘SgzŠÂŒŒŠÔ‚Ì–ò•¨ˆÚs“®‘Ô‚É‹y‚Ú‚·Ž‰–b“û܂̉e‹¿F• o“à“Š—^Žž‚̈Ús“®‘Ô.
‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïC_ŒËC10.1-2, 2011.
164) ›X‘×—TA¬ì“ÖA‚‹´•‘AXŽR‘ˆê˜YA㌴–ƒ–¢A’†ŽRË]A‡—t“N–çA•è—E“ñF
L-HPCŠÜ…ƒQƒ‹ƒV[ƒg‚ÌŽ¼—Ö@—p”í•¢Œ^ŠO—pŠî܂Ƃµ‚Ă̻ܓI“Á«.
‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïC_ŒËC10.1-2, 2011.
163) ›‚‹´KˆêA“n•Ó‘PÆA•ú±—E“ñA’|“à—m•¶F
‹³ˆç•ª‰È‰ï‚©‚ç‚Ì’ñŒ¾.
“ú–{–òÜŠw‰ï‘æ26”N‰ïi–òŠw‹³ˆçƒVƒ“ƒ|ƒWƒEƒ€u–òŠw•”‹³ˆç‚É‘±‚V‘åŠw‰@‰Û’ö‚ł̋³ˆç‚ÆŒ¤‹†FŠî‘b‚Æ‚µ‚Ă̊w•”‹³ˆç‚©‚çV¶‘åŠw‰@‹³ˆç‚ÖvjC“Œ‹žC5.29-31, 2011.
162) ›–q”V’iŒhˆêA“Œ‰¶”[@ŽiA‘ºãm”üA‡—t“N–çA•ú±—E“ñF
–ò•¨‚̋ؓ÷“àŠgŽUE•ª•z“®‘Ô‚É‹y‚Ú‚·ŒŒ—¬—ʂ̉e‹¿F‹ÇŠ—â‹pŽž‚Ì“®‘Ô“Á«.
“ú–{–òÜŠw‰ï‘æ26”N‰ïC“Œ‹žC5.29-31, 2011.
@@@@@
y•½¬22”N“xz
161) ›•ú±—E“ñA•x‰ª‰À‹vAŽO“c’q•¶A–k‘º‰À‹vF
‘—§‘åŠw‚É‚¨‚¯‚éu’·Šú‰Û‘茤‹†‹y‚уAƒhƒoƒ“ƒXƒg‹³ˆçƒvƒƒOƒ‰ƒ€v‚ÌŒ»ó.
“ú–{–òŠw‰ï‘æ131”N‰ïiƒVƒ“ƒ|ƒWƒEƒ€u擱“I–òÜŽt—{¬‚ÉŒü‚¯‚½ŽÀ‘H“IƒAƒhƒoƒ“ƒXƒg‹³ˆçƒvƒƒOƒ‰ƒ€‚Ì‹¤“¯ŠJ”vjCɪŽsC3.28-31, 2011.
160) ›Šì“TŽqA‘êˆêAo‰H—SŠîA‡—t“N–çAì蔎ŒÈA•ú±—E“ñF
ƒ‰ƒbƒg‚É‚¨‚¯‚é–ò•¨ŠÌ‘ãŽÓy‘f‚Ì”Œ»‚É‹y‚Ú‚·‹}«t•s‘S‚̉e‹¿.
“ú–{–òŠw‰ï‘æ131”N‰ïCɪŽsC3.28-31, 2011.
159) ›Œã“¡—SŽqA‘C“c‚ ‚ä‚ÝA‡—t“N–çA•ú±—E“ñF
ƒ‰ƒbƒg‚É‚¨‚¯‚éƒLƒgƒTƒ“‚̃AƒVƒNƒƒrƒ‹Á‰»ŠÇ‹zŽû‘£i‹@\‚ÌŒŸ“¢.
“ú–{–òŠw‰ï‘æ131”N‰ïCɪŽsC3.28-31, 2011.
158) ›Šì“TŽqA‘êˆêAo‰H—SŠîA‡—t“N–çAì蔎ŒÈA•ú±—E“ñF
ƒ‰ƒbƒg‚É‚¨‚¯‚é–ò•¨ŠÌ‘ãŽÓŠˆ«‚É‹y‚Ú‚·‹}«t•s‘S‚̉e‹¿.
‘æ49‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC•ÄŽqŽsC11.6-7, 2010.
157) ›‰ª@‘åŽkA¬—Ñ@“OA‡—t“N–çA•ú±—E“ñF
މ–b“ûÜ‚ð—p‚¢‚½”÷¬“§Í–@iLipo-MD–@jF–ò•¨‚ÌŽ‰—n«‚ª“§Í“Á«‚É‹y‚Ú‚·‰e‹¿.
‘æ49‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC•ÄŽqŽsC11.6-7, 2010.
156) ›‚”¨—F‹IŽqAXŽR‘ˆê˜YA–x“àŽ÷A‡—t“N–çA•ú±—E“ñF
މ–b“ûÜ‚ð—p‚¢‚½• –Œ“§Í‚ªŽ‰—n«–ò•¨‚ÌŒŒŸ÷’†”Z“x„ˆÚ‚É‹y‚Ú‚·‰e‹¿.
‘æ49‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC•ÄŽqŽsC11.6-7, 2010.
155) ›Œã“¡—SŽqA‘C“c‚ ‚ä‚ÝA‡—t“N–çA•ú±—E“ñF
In vivo‚É‚¨‚¯‚éƒLƒgƒTƒ“‚̃AƒVƒNƒƒrƒ‹‹zŽû‘£i‹@\‚ÌŒŸ“¢.
‘æ49‰ñ“ú–{–òŠw‰ïE“ú–{–òÜŽt‰ïE“ú–{•a‰@–òÜŽt‰ï’†‘Žl‘Žx•”Šwp‘å‰ïC•ÄŽqŽsC11.6-7, 2010.
154) ›Jun-ichi Kusaba, Noriko Kajikawa, Yuki Izuwa, Tetsuya Aiba, Hiromu Kawasaki and Yuji Kurosaki:
Altered drug metabolizing activity of hepatic CYP3A subfamily in rats with acute renal failure.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ25‰ñ”N‰ïC“Œ‹žC10.7-9, 2010.
153) ›Tsukasa Higashionna, Hitomi Murakami, Keiichi Makinodan, Kozue Kanda, Mayu Shibata, Tetsuya Aiba and Yuji Kurosaki:
Microdialysis study in evaluation of intramuscular lateral distribution profiles of topically administered drugs in rats.
“ú–{–ò•¨“®‘ÔŠw‰ï‘æ25‰ñ”N‰ïC“Œ‹žC10.7-9, 2010.
152) ›ê “c’ŽuA㓇 ’qA²“¡’qºA‡—t“N–çA•è—E“ñA¼‰i ®Aç“°”NºF
¬Ž™‚É‚¨‚¯‚éƒeƒCƒRƒvƒ‰ƒjƒ“‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ|ŒŒ’†”Z“x‚É‹y‚Ú‚·Šî‘b޾г‚̉e‹¿|.
‘æ27‰ñ“ú–{‚s‚c‚lŠw‰ïEŠwp‘å‰ïCŽD–yŽsC6.26-27, 2010.
151) ›X@‘×—TAXŽR‘ˆê˜YA㌴–ƒ–¢A’†ŽRË]A‡—t“N–çA•ú±—E“ñF
L-HPCŠÜ…ƒQƒ‹ƒV[ƒg‚Ì’²»‚Ɣ핢Œ^ŠO—pŠî܂Ƃµ‚Ă̻ܓI“Á«•]‰¿.
“ú–{–òÜŠw‰ï‘æ25”N‰ïC“¿“‡ŽsC5.12-14, 2010.
150) ›‘C“c‚ ‚ä‚ÝA‡—t“N–çA•ú±—E“ñF
In vivo‚É‚¨‚¯‚é“ï‹zŽû«RƒEƒBƒ‹ƒX–ò‚̃oƒCƒIƒAƒxƒCƒ‰ƒrƒŠƒeƒB‰ü‘P‚ÌŽŽ‚Ý.
“ú–{–òÜŠw‰ï‘æ25”N‰ïC“¿“‡ŽsC5.12-14, 2010.